Source:http://linkedlifedata.com/resource/pubmed/id/19237628
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2009-3-31
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1527-7755
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1534-6
|
| pubmed:meshHeading |
pubmed-meshheading:19237628-Antibodies, Monoclonal,
pubmed-meshheading:19237628-Bone Density Conservation Agents,
pubmed-meshheading:19237628-Bone Neoplasms,
pubmed-meshheading:19237628-Clinical Trials as Topic,
pubmed-meshheading:19237628-Humans,
pubmed-meshheading:19237628-Osteoporosis,
pubmed-meshheading:19237628-RANK Ligand
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
|
| pubmed:publicationType |
Editorial,
Comment
|